Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease,
despite the improvement of multi-modality treatment strategies, the prognosis of pancreatic …

Pancreatic ductal adenocarcinoma (PDAC) ranks among the 15 most prevalent cancers
globally, characterized by aggressive growth and late-stage diagnosis. Advances in imaging …

Importance There are currently no clinically relevant criteria to predict a futile up-front
pancreatectomy in patients with anatomically resectable pancreatic ductal adenocarcinoma …

Simple Summary Pancreatic ductal adenocarcinoma is a very lethal tumor entity with the late
appearance of clinical signs and the absence of biomarkers for early diagnosis. Diabetes …

Simple Summary Pancreatic cancer presents a challenge due to its high mortality rates and
limited treatment options. In an effort to improve patient outcomes, neoadjuvant treatment …

Death from pancreatic adenocarcinoma (PDAC) is predicted to surpass colorectal cancer to
become the second leading cause of cancer-related death by 2030. 1 The incidence of …

Cancers of the digestive system are major contributors to global cancer-associated morbidity
and mortality, accounting for 35% of annual cases of cancer deaths. The etiologies …

Neoadjuvant therapy (NAT) for early-stage pancreatic ductal adenocarcinoma (PDA) has
recently gained prominence. We investigated the clinical significance of mucin 5 AC …

Pancreatic cancer (PC) is a highly aggressive and lethal malignancy characterized by a
complex tumor microenvironment (TME) and immunosuppressive features that limit the …

Traditional chemotherapy-based adjuvant therapies for locally advanced pancreatic ductal
adenocarcinoma (PDAC) have been associated with poor clinical outcomes driven partly by …